ipi-145 profile

ID Source	ID
PubMed CID	50905713
CHEMBL ID	3039502
CHEBI ID	131169
SCHEMBL ID	153543
SCHEMBL ID	18343557
SCHEMBL ID	19670020
SCHEMBL ID	20580104
MeSH ID	M0591924

Synonym
duvelisib ,
HY-17044
CHEBI:131169
SJVQHLPISAIATJ-ZDUSSCGKSA-N
CS-0888
S7028
ink-1147
CHEMBL3039502
ipi-145
ink-1197
unii-610v23s0ji
8-chloro-2-phenyl-3-((1s)-1-(7h-purin-6-ylamino)ethyl)isoquinolin-1(2h)-one
duvelisib [usan:inn]
1201438-56-3
610v23s0ji ,
1(2h)-isoquinolinone, 8-chloro-2-phenyl-3-((1s)-1-(9h-purin-6-ylamino)ethyl)-
8-chloro-2-phenyl-3-((1s)-1-(9h-purin-6-ylamino)ethyl)-1(2h)-isoquinolinone
gtpl7795
(s)-3-(1-((9h-purin-6-yl)amino)ethyl)-8-chloro-2-phenylisoquinolin-1(2h)-one
compound 4904 [patent us8193182]
AKOS022186370
SCHEMBL153543
duvelisib [orange book]
duvelisib [who-dd]
duvelisib [usan]
duvelisib [mi]
duvelisib [inn]
(s)-3-(1-(9h-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2h)-one
ipi145
ipi-145 (ink1197)
ipi 145
duvelisib (usan/inn)
D10555
AC-30239
ipi-145;ink1197
DTXSID80152697 ,
ink1197
SCHEMBL18343557
mfcd15144635
SCHEMBL19670020
NCGC00351482-01
bdbm50193013
SW219822-1
duvelisib (ipi-145, ink1197)
DB11952
SCHEMBL20580104
BCP07042
ipi-145 pound>>ink1197; ipi 145; ipi145; ink-1197; ink 1197
EX-A1562
ipi-145, ink 1197, duvelisib
Q27077129
AS-16309
AMY24208
1(2h)-isoquinolinone, 8-chloro-2-phenyl-3-[(1s)-1-(9h-purin-6-ylamino)ethyl]-
CCG-268854
8-chloro-2-phenyl-3-[(1s)-1-(7h-purin-6-ylamino)ethyl]isoquinolin-1-one
AKOS037515795
nsc772469
nsc-772469
duvelisib (ipi-145)
EN300-18167128
8-chloro-2-phenyl-3-[(1s)-1-[(9h-purin-6-yl)amino]ethyl]-1,2-dihydroisoquinolin-1-one
compound 4904 (patent us8193182)
duvelisibum
dtxcid2075188
8-chloro-2-phenyl-3-[(1s)-1-[(9h-purin-6-yl)amino]ethyl]isoquinolin-1-one

Excerpt	Reference	Relevance
" Primary safety outcomes included risk of grade ≥ 3 treatment-emergent adverse events (TEAEs); primary efficacy outcomes included objective response rate (ORR)."	( A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3- Adib, D; Gupta, D; Mamlouk, K; Nellesen, D; Proudman, D; Yang, J, 2022)	0.72
" For safety analysis, the incidences of any grade and grade ≥3 adverse events (AEs), serious AEs, and treatment-related discontinuation and death were evaluated."	( Safety and efficacy of dual PI3K-δ, γ inhibitor, duvelisib in patients with relapsed or refractory lymphoid neoplasms: A systematic review and meta-analysis of prospective clinical trials. Niu, T; Wang, J; Wang, Z; Xu, J; Zhou, H, 2022)	0.72

Excerpt	Reference	Relevance
" In literature, there is no method valid for quantitation of DUV in human plasma for its therapeutic monitoring and pharmacokinetic studies."	( A Highly Sensitive Nonextraction-Assisted HPLC Method with Fluorescence Detection for Quantification of Duvelisib in Plasma Samples and its Application to Pharmacokinetic Study in Rats. Almehizia, AA; Almomen, A; Alzoman, NZ; Darwish, IA; Khalil, NY; Sayed, AY, 2021)	0.62
"The purpose of this study is the establishment of a highly sensitive HPLC method with fluorescence detection for quantitation of DUV in plasma for its therapeutic monitoring and pharmacokinetic studies of DUV."	( A Highly Sensitive Nonextraction-Assisted HPLC Method with Fluorescence Detection for Quantification of Duvelisib in Plasma Samples and its Application to Pharmacokinetic Study in Rats. Almehizia, AA; Almomen, A; Alzoman, NZ; Darwish, IA; Khalil, NY; Sayed, AY, 2021)	0.62

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Excerpt	Relevance	Reference
" IPI-145 significantly reduced arthritis severity in both RA models using dosing regimens initiated before onset of clinical disease."	( Novel phosphoinositide 3-kinase δ,γ inhibitor: potent anti-inflammatory effects and joint protection in models of rheumatoid arthritis. Bartok, B; Boyle, DL; Firestein, GS; Kim, HR; Topolewski, K, 2014)	1.31
" Duvelisib represents a highly active agent, and ongoing investigations, including fixed-duration drug combinations and alternative dosing schedules, are aimed at reducing immune-mediated toxicities."	( Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma. Danilov, AV; Pagel, JM; Patel, K, 2019)	0.51

Class	Description
isoquinolines	A class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average (µ)	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
PPM1D protein	Homo sapiens (human)	Potency	1.8557	0.0052	9.4661	32.9993	AID1347411
cytochrome P450 family 3 subfamily A polypeptide 4	Homo sapiens (human)	Potency	2.3919	0.0123	7.9835	43.2770	AID1645841
G	Vesicular stomatitis virus	Potency	0.7564	0.0123	8.9648	39.8107	AID1645842
Interferon beta	Homo sapiens (human)	Potency	1.5809	0.0033	9.1582	39.8107	AID1347411; AID1645842
HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)	Potency	0.7564	0.0123	8.9648	39.8107	AID1645842
Inositol hexakisphosphate kinase 1	Homo sapiens (human)	Potency	0.7564	0.0123	8.9648	39.8107	AID1645842
cytochrome P450 2C9, partial	Homo sapiens (human)	Potency	0.7564	0.0123	8.9648	39.8107	AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)	IC50 (µMol)	0.0147	0.0001	0.3371	7.3000	AID1317009; AID1339847; AID1421360; AID1534886; AID1553529; AID1555050; AID1555052; AID1555059; AID1870047; AID1894167
Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)	IC50 (µMol)	1.4450	0.0000	0.6832	10.0000	AID1339847; AID1339848; AID1339849; AID1421358; AID1421359; AID1421360; AID1555050; AID1555052
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)	IC50 (µMol)	4.0007	0.0000	0.7340	10.0000	AID1339848; AID1421358; AID1534890
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)	IC50 (µMol)	0.2855	0.0002	0.5953	10.0000	AID1339849; AID1421359; AID1534891; AID1555050
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)	IC50 (µMol)	0.0232	0.0003	0.6607	10.0000	AID1317010; AID1339846; AID1421361; AID1534885; AID1553530; AID1555050; AID1555051; AID1870046; AID1894168
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
natural killer cell differentiation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of cytokine production	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of endothelial cell proliferation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
adaptive immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
mast cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
respiratory burst involved in defense response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
protein phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
inflammatory response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of endothelial cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of gene expression	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
T cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
natural killer cell activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
B cell differentiation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
T cell differentiation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
neutrophil chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of neutrophil apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
natural killer cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
B cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
vascular endothelial growth factor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
T cell activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
B cell activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
mast cell degranulation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
innate immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of angiogenesis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
T cell receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
B cell receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
mast cell differentiation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
neutrophil extravasation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
positive regulation of epithelial tube formation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell activation involved in immune response	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway	Interferon beta	Homo sapiens (human)
cell surface receptor signaling pathway via JAK-STAT	Interferon beta	Homo sapiens (human)
response to virus	Interferon beta	Homo sapiens (human)
positive regulation of autophagy	Interferon beta	Homo sapiens (human)
cytokine-mediated signaling pathway	Interferon beta	Homo sapiens (human)
natural killer cell activation	Interferon beta	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT protein	Interferon beta	Homo sapiens (human)
cellular response to interferon-beta	Interferon beta	Homo sapiens (human)
B cell proliferation	Interferon beta	Homo sapiens (human)
negative regulation of viral genome replication	Interferon beta	Homo sapiens (human)
innate immune response	Interferon beta	Homo sapiens (human)
positive regulation of innate immune response	Interferon beta	Homo sapiens (human)
regulation of MHC class I biosynthetic process	Interferon beta	Homo sapiens (human)
negative regulation of T cell differentiation	Interferon beta	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Interferon beta	Homo sapiens (human)
defense response to virus	Interferon beta	Homo sapiens (human)
type I interferon-mediated signaling pathway	Interferon beta	Homo sapiens (human)
neuron cellular homeostasis	Interferon beta	Homo sapiens (human)
cellular response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
cellular response to virus	Interferon beta	Homo sapiens (human)
negative regulation of Lewy body formation	Interferon beta	Homo sapiens (human)
negative regulation of T-helper 2 cell cytokine production	Interferon beta	Homo sapiens (human)
positive regulation of apoptotic signaling pathway	Interferon beta	Homo sapiens (human)
response to exogenous dsRNA	Interferon beta	Homo sapiens (human)
B cell differentiation	Interferon beta	Homo sapiens (human)
natural killer cell activation involved in immune response	Interferon beta	Homo sapiens (human)
adaptive immune response	Interferon beta	Homo sapiens (human)
T cell activation involved in immune response	Interferon beta	Homo sapiens (human)
humoral immune response	Interferon beta	Homo sapiens (human)
positive regulation of T cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
adaptive immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of T cell anergy	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
defense response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
detection of bacterium	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-12 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of interleukin-6 production	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protection from natural killer cell mediated cytotoxicity	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
innate immune response	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
regulation of dendritic cell differentiation	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class Ib	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
intracellular glucose homeostasis	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
negative regulation of cell-matrix adhesion	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of leukocyte migration	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
transcription by RNA polymerase II	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
protein import into nucleus	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
immune response	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
extrinsic apoptotic signaling pathway via death domain receptors	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of lamellipodium assembly	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
cytokine-mediated signaling pathway	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
B cell differentiation	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
T cell differentiation	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
osteoclast differentiation	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
cellular response to insulin stimulus	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of RNA splicing	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
regulation of toll-like receptor 4 signaling pathway	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
substrate adhesion-dependent cell spreading	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
cellular response to UV	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
response to endoplasmic reticulum stress	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
interleukin-18-mediated signaling pathway	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
natural killer cell mediated cytotoxicity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of protein import into nucleus	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
negative regulation of apoptotic process	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
negative regulation of osteoclast differentiation	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of transcription by RNA polymerase II	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of glucose import	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
protein stabilization	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of filopodium assembly	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
negative regulation of stress fiber assembly	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
growth hormone receptor signaling pathway	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
myeloid leukocyte migration	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of focal adhesion disassembly	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of endoplasmic reticulum unfolded protein response	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
positive regulation of protein localization to plasma membrane	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
insulin receptor signaling pathway	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
angiogenesis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
liver development	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
regulation of protein phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
vasculature development	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
glucose metabolic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phagocytosis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
epidermal growth factor receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
insulin receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
positive regulation of lamellipodium assembly	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of gene expression	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to muscle inactivity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of macroautophagy	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
actin cytoskeleton organization	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
platelet activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of actin filament depolymerization	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
T cell costimulation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
positive regulation of TOR signaling	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cellular response to insulin stimulus	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to muscle stretch	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
vascular endothelial growth factor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
regulation of multicellular organism growth	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to L-leucine	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
anoikis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
regulation of cellular respiration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of neuron apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
endothelial cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
insulin-like growth factor receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
positive regulation of smooth muscle cell proliferation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
T cell receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
relaxation of cardiac muscle	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cardiac muscle contraction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
adipose tissue development	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cellular response to glucose stimulus	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cellular response to hydrostatic pressure	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to dexamethasone	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cardiac muscle cell contraction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
energy homeostasis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
regulation of actin filament organization	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
autosome genomic imprinting	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
response to butyrate	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
positive regulation of protein localization to membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of fibroblast apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
negative regulation of anoikis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
regulation of cell-matrix adhesion	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of gene expression	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of nitric oxide biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
endothelial cell proliferation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
response to ischemia	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
intracellular calcium ion homeostasis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
endocytosis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
autophagy	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
homophilic cell adhesion via plasma membrane adhesion molecules	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of autophagy	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of endothelial cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
platelet activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of neutrophil apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
positive regulation of Rac protein signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
embryonic cleavage	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
negative regulation of MAPK cascade	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
angiogenesis involved in wound healing	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
platelet aggregation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
negative regulation of vascular endothelial growth factor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
negative regulation of hypoxia-induced intrinsic apoptotic signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
negative regulation of sprouting angiogenesis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
regulation of clathrin-dependent endocytosis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphorylation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
angiogenesis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of cytokine production	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
adaptive immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
dendritic cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of acute inflammatory response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
respiratory burst involved in defense response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
sphingosine-1-phosphate receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
endocytosis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
inflammatory response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of cytosolic calcium ion concentration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of endothelial cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
T cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
negative regulation of triglyceride catabolic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
neutrophil chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
secretory granule localization	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
regulation of cell adhesion mediated by integrin	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of Rac protein signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
natural killer cell chemotaxis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
T cell proliferation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
T cell activation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
mast cell degranulation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of MAP kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
innate immune response	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
regulation of angiogenesis	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
negative regulation of cardiac muscle contraction	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
platelet aggregation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
cellular response to cAMP	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
neutrophil extravasation	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
hepatocyte apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
regulation of calcium ion transmembrane transport	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
negative regulation of fibroblast apoptotic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
cell migration	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol-mediated signaling	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol-3-phosphate biosynthetic process	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
inositol phosphate metabolic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
negative regulation of cold-induced thermogenesis	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol phosphate biosynthetic process	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
ATP binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
1-phosphatidylinositol-3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
cytokine activity	Interferon beta	Homo sapiens (human)
cytokine receptor binding	Interferon beta	Homo sapiens (human)
type I interferon receptor binding	Interferon beta	Homo sapiens (human)
protein binding	Interferon beta	Homo sapiens (human)
chloramphenicol O-acetyltransferase activity	Interferon beta	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
signaling receptor binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
peptide antigen binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
TAP binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
protein-folding chaperone binding	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phosphotyrosine residue binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
transmembrane receptor protein tyrosine kinase adaptor activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
insulin receptor binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
insulin-like growth factor receptor binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
neurotrophin TRKA receptor binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
protein binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
kinase activator activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
protein phosphatase binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol 3-kinase regulator activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol 3-kinase regulatory subunit binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
ErbB-3 class receptor binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol 3-kinase binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
insulin binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
insulin receptor substrate binding	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
protein heterodimerization activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol kinase activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
enzyme-substrate adaptor activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol 3-kinase activator activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
1-phosphatidylinositol-3-kinase regulator activity	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
protein serine/threonine kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
protein binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
ATP binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
1-phosphatidylinositol-3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
protein kinase activator activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
insulin receptor substrate binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
protein serine kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
protein binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
ATP binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
1-phosphatidylinositol-3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
insulin receptor substrate binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
protein serine kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
protein kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
protein serine/threonine kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
protein binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
ATP binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
1-phosphatidylinositol-3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
1-phosphatidylinositol-4-phosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
identical protein binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
ephrin receptor binding	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
1-phosphatidylinositol-4,5-bisphosphate 3-kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
protein serine kinase activity	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol heptakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
protein binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
ATP binding	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 1-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol hexakisphosphate 3-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activity	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
cytosol	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IA	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform	Homo sapiens (human)
extracellular space	Interferon beta	Homo sapiens (human)
extracellular region	Interferon beta	Homo sapiens (human)
Golgi membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
endoplasmic reticulum	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
Golgi apparatus	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
cell surface	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
ER to Golgi transport vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
secretory granule membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
phagocytic vesicle membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
early endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
recycling endosome membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular exosome	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
lumenal side of endoplasmic reticulum membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
MHC class I protein complex	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
extracellular space	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
external side of plasma membrane	HLA class I histocompatibility antigen, B alpha chain	Homo sapiens (human)
nucleus	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
cis-Golgi network	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
cytosol	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
cell-cell junction	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IA	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
membrane	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
perinuclear region of cytoplasm	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
perinuclear endoplasmic reticulum membrane	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
phosphatidylinositol 3-kinase complex	Phosphatidylinositol 3-kinase regulatory subunit alpha	Homo sapiens (human)
cytosol	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IA	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
intercalated disc	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
lamellipodium	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
perinuclear region of cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IB	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform	Homo sapiens (human)
nucleus	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
nucleoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
nucleolus	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
cytosol	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IA	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
midbody	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
intracellular membrane-bounded organelle	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
cytosol	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IA	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
phosphatidylinositol 3-kinase complex, class IB	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
plasma membrane	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
cytoplasm	Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	Homo sapiens (human)
fibrillar center	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytosol	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
nucleus	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
cytoplasm	Inositol hexakisphosphate kinase 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (73)

Assay ID	Title	Year	Journal	Article
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347160	Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008	Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening	2020	SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1	Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347159	Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay	2020	Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49	Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1869969	Inhibition of N-terminal His6-tagged recombinant full length human PI3Kdelta expressed in baculovirus infected Sf21 insect cells at 1 uM by HTRF assay relative to control	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1555068	Inhibition of PI3Kdelta in human whole blood assessed as reduction in fMLP-stimulated CD63 expression in basophils preincubated for 30 mins followed by fMLP stimulation	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
AID1317009	Inhibition of human PI3Kdelta (R108 to Q1044 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay
AID1555055	Inhibition of N-terminal His6-tagged recombinant full length human p110delta/untagged recombinant full length human p85alpha expressed in baculovirus infected Sf21 insect cells at 1 uM using PIP2 as substrate measured after 80 mins by transcreener fluores	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
AID1869964	Inhibition of N-terminal His6-tagged recombinant full length human PI3Kgamma expressed in baculovirus infected Sf21 insect cells at 0.1 uM by HTRF assay relative to control	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1870047	Inhibition of N-terminal His6-tagged recombinant full length human PI3Kdelta expressed in baculovirus infected Sf21 insect cells incubated for 30 mins by HTRF assay	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1555052	Inhibition of N-terminal His6-tagged recombinant full length human p110delta/untagged recombinant full length human p85alpha expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate measured after 80 mins by transcreener fluorescence po	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
AID1553531	Selectivity ratio of IC50 for PI3Kalpha in human Raji cells to IC50 for PI3Kdelta in human Raji cells	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases.
AID1869970	Inhibition of N-terminal His6-tagged recombinant full length human PI3Kdelta expressed in baculovirus infected Sf21 insect cells at 0.1 uM by HTRF assay relative to control	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1555050	Inhibition of N-terminal His6-tagged recombinant full length human p110beta/untagged recombinant full length human p85alpha expressed in baculovirus infected Sf21 insect cells using PIP2 as substrate measured after 80 mins by transcreener fluorescence pol	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
AID1317034	Antiproliferative activity against human Loucy cells after 3 days by CellTiter-Glo assay
AID1636709	Inhibition of PI3Kgamma/delta in human whole blood assessed as inhibition of FcepsilonR1/fMLP-stimulated basophil degranulation by measuring CD63+ cells	2016	Journal of medicinal chemistry, 08-11, Volume: 59, Issue:15	Evolution of a Novel, Orally Bioavailable Series of PI3Kδ Inhibitors from an Inhaled Lead for the Treatment of Respiratory Disease.
AID1553532	Selectivity ratio of IC50 for PI3Kbeta in human Raji cells to IC50 for PI3Kdelta in human Raji cells	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases.
AID1869968	Antiproliferative activity against human SU-DHL-4 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1317027	Inhibition of p110beta in HMEC assessed as reduction in Akt phosphorylation at Ser-473 residue at 0.01 to 1 uM after 1 hr by Western blot analysis
AID1870035	Selectivity ratio of IC50 for N-terminal His6-tagged recombinant full length human PI3Kalpha expressed in baculovirus infected Sf21 insect cells to IC50 for N-terminal His6-tagged recombinant full length human PI3Kgamma expressed in baculovirus infected S	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1553529	Inhibition of PI3Kdelta in human Raji cells	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases.
AID1870037	Antiproliferative activity against human SUDHL2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1555064	Inhibition of PI3Kdelta in human whole blood assessed as reduction in anti-IgM-stimulated CD69 expression on B-cells preincubated for 60 mins followed by anti-IgM stimulation and measured after overnight incubation by flow cytometry	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
AID1869965	Inhibition of N-terminal His6-tagged recombinant full length human PI3Kgamma expressed in baculovirus infected Sf21 insect cells at 1 uM by HTRF assay relative to control	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1317035	Antiproliferative activity against patient-derived IgM-stimulated CLL cells after 3 days by CellTiter-Glo assay
AID1317031	Antiproliferative activity against human MOLT4 cells after 3 days by CellTiter-Glo assay
AID1534886	Inhibition of PI3Kdelta (unknown origin)	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Targeting the immunity protein kinases for immuno-oncology.
AID1317030	Antiproliferative activity against human Jurkat cells after 3 days by CellTiter-Glo assay
AID1421361	Inhibition of PI3KCgamma (unknown origin)	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Piperidinyl-embeded chalcones possessing anti PI3Kδ inhibitory properties exhibit anti-atopic properties in preclinical models.
AID1555059	Inhibition of PI3Kdelta in human Ramos cells assessed as reduction in antihuman IgM-stimulated AKT phosphorylation at Ser473 residue preincubated for 60 mins followed by antihuman IgM stimulation and measured after 15 mins	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
AID1317028	Inhibition of p110beta in HMEC assessed as reduction in Akt phosphorylation at Thr-308 residue at 0.01 to 1 uM after 1 hr by Western blot analysis
AID1421359	Inhibition of PI3KCbeta/PIK3R1 (unknown origin)	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Piperidinyl-embeded chalcones possessing anti PI3Kδ inhibitory properties exhibit anti-atopic properties in preclinical models.
AID1525582	Antifibrotic activity against mouse Mlg2908 cells assessed as reduction in cell viability measured after 72 hrs by MTT assay	2019	Journal of medicinal chemistry, 10-10, Volume: 62, Issue:19	Discovery of 4-Methylquinazoline Based PI3K Inhibitors for the Potential Treatment of Idiopathic Pulmonary Fibrosis.
AID1869972	Inhibition of N-terminal His6-tagged recombinant full length human PI3Kbeta expressed in baculovirus infected Sf21 insect cells at 1 uM by HTRF assay relative to control	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1553533	Cytotoxicity against in human Raji cells	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases.
AID1894167	Inhibition of p110delta (unknown origin)	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
AID1870039	Selectivity ratio of IC50 for human SKOV-3 cells over expressing PI3Kalpha to IC50 for human SUDHL-6 cells	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1534890	Inhibition of PI3Kalpha (unknown origin)	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Targeting the immunity protein kinases for immuno-oncology.
AID1555067	Inhibition of PI3Kgamma in human whole blood assessed as reduction in anti-IgE-stimulated CD63 expression in basophils preincubated for 30 mins followed by anti-IgE stimulation	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
AID1869967	Antiproliferative activity against human SU-DHL-6 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1421360	Inhibition of PI3KCdelta/PIK3R1 (unknown origin)	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Piperidinyl-embeded chalcones possessing anti PI3Kδ inhibitory properties exhibit anti-atopic properties in preclinical models.
AID1555056	Inhibition of N-terminal His6-tagged recombinant full length human p110beta/untagged recombinant full length human p85alpha expressed in baculovirus infected Sf21 insect cells at 1 uM using PIP2 as substrate measured after 80 mins by transcreener fluoresc	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
AID1870038	Selectivity ratio of IC50 for human 786-O cells over expressing PI3Kbeta to IC50 for human SU-DHL-6 cells	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1534885	Inhibition of PI3Kgamma (unknown origin)	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Targeting the immunity protein kinases for immuno-oncology.
AID1421358	Inhibition of PI3KCalpha/PIK3R1 (unknown origin)	2018	European journal of medicinal chemistry, Oct-05, Volume: 158	Piperidinyl-embeded chalcones possessing anti PI3Kδ inhibitory properties exhibit anti-atopic properties in preclinical models.
AID1553492	Selectivity ratio of IC50 for PI3Kalpha (unknown origin) to IC50 for PI3Kdelta (unknown origin)	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases.
AID1317033	Antiproliferative activity against human MOLM14 cells after 3 days by CellTiter-Glo assay
AID1553493	Selectivity ratio of IC50 for PI3Kbeta (unknown origin) to IC50 for PI3Kdelta (unknown origin)	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases.
AID1555051	Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
AID1870046	Inhibition of N-terminal His6-tagged recombinant full length human PI3Kgamma expressed in baculovirus infected Sf21 insect cells incubated for 30 mins by HTRF assay	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1869966	Antiproliferative activity against human DOHH-2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1317010	Inhibition of human PI3Kgamma (S144 to A1102 residues) expressed in mammalian expression system incubated for 60 mins by ADAPTA assay
AID1555065	Inhibition of PI3Kdelta in rat whole blood assessed as reduction in anti-IgD-stimulated CD86 expression on B-cells preincubated for 60 mins followed by anti-IgD stimulation and measured after overnight incubation by flow cytometry	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
AID1870036	Selectivity ratio of IC50 for N-terminal His6-tagged recombinant full length human PI3Kbeta expressed in baculovirus infected Sf21 insect cells to IC50 for N-terminal His6-tagged recombinant full length human PI3Kgamma expressed in baculovirus infected Sf	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1317029	Inhibition of p110beta in HMEC assessed as reduction in S6RP phosphorylation at Ser-235/236 residue at 0.01 to 1 uM after 1 hr by Western blot analysis
AID1555061	Stability in human liver microsomes assessed as parent compound remaining at 1 uM measured after 30 mins in presence of NADPH generating system	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
AID1317032	Antiproliferative activity against human MV4-11 cells after 3 days by CellTiter-Glo assay
AID1869971	Inhibition of N-terminal His6-tagged recombinant full length human PI3Kalpha expressed in baculovirus infected Sf21 insect cells at 1 uM by HTRF assay relative to control	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1894168	Inhibition of p110gamma (unknown origin)	2021	European journal of medicinal chemistry, Mar-15, Volume: 214	FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.
AID1534891	Inhibition of PI3Kbeta (unknown origin)	2019	European journal of medicinal chemistry, Feb-01, Volume: 163	Targeting the immunity protein kinases for immuno-oncology.
AID1555054	Inhibition of recombinant human full-length His-tagged PI3K p110gamma expressed in baculovirus expression system at 1 uM using PIP2 as substrate measured after 80 mins by transcreener fluorescence polarization assay relative to control	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
AID1869973	Metabolic stability in human liver microsomes assessed as clearance at 1 uM measured upto 60 mins in presence of NADPH by measuring protein	2022	Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14	Discovery, Optimization, and Evaluation of Potent and Selective PI3Kδ-γ Dual Inhibitors for the Treatment of B-cell Malignancies.
AID1555058	Inhibition of PI3Kgamma in rat RAW264.7 cells assessed as reduction in C5a-stimulated AKT phosphorylation at Ser473 residue preincubated for 30 mins followed by C5a-stimulation and measured after 5 mins	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
AID1555060	Stability in rat liver microsomes assessed as parent compound remaining at 1 uM measured after 30 mins in presence of NADPH generating system	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Discovery, Optimization, and Evaluation of Potent and Highly Selective PI3Kγ-PI3Kδ Dual Inhibitors.
AID1553530	Inhibition of PI3Kgamma in human Raji cells	2019	Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10	Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases.
AID1347414	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Secondary screen by immunofluorescence	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347411	qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347412	qHTS assay to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: Counter screen cell viability and HiBit confirmation	2020	ACS chemical biology, 07-17, Volume: 15, Issue:7	High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1345778	Human phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta (Phosphatidylinositol kinases)	2013	Chemistry & biology, Nov-21, Volume: 20, Issue:11	PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.
AID1345786	Human phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma (Phosphatidylinositol kinases)	2013	Chemistry & biology, Nov-21, Volume: 20, Issue:11	PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.
AID1345748	Human phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta (Phosphatidylinositol kinases)	2013	Chemistry & biology, Nov-21, Volume: 20, Issue:11	PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.
AID1345749	Human phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (Phosphatidylinositol kinases)	2013	Chemistry & biology, Nov-21, Volume: 20, Issue:11	PI3K-δ and PI3K-γ inhibition by IPI-145 abrogates immune responses and suppresses activity in autoimmune and inflammatory disease models.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	47 (60.26)	24.3611
2020's	31 (39.74)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	14 (17.95%)	5.53%
Reviews	12 (15.38%)	6.00%
Case Studies	5 (6.41%)	4.05%
Observational	0 (0.00%)	0.25%
Other	47 (60.26%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
adenine [no description available]	7.18	8	2	6-aminopurines; purine nucleobase	Daphnia magna metabolite; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
hydrogen Hydrogen: The first chemical element in the periodic table with atomic symbol H, and atomic number 1. Protium (atomic weight 1) is by far the most common hydrogen isotope. Hydrogen also exists as the stable isotope DEUTERIUM (atomic weight 2) and the radioactive isotope TRITIUM (atomic weight 3). Hydrogen forms into a diatomic molecule at room temperature and appears as a highly flammable colorless and odorless gas.. dihydrogen : An elemental molecule consisting of two hydrogens joined by a single bond.	2.41	1	0	elemental hydrogen; elemental molecule; gas molecular entity	antioxidant; electron donor; food packaging gas; fuel; human metabolite
mitotane Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.	2.31	1	0	diarylmethane
thalidomide Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.	3.21	1	0	phthalimides; piperidones
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	2.31	1	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
quinoxalines quinoxaline : A naphthyridine in which the nitrogens are at positions 1 and 4.	2.17	1	0	mancude organic heterobicyclic parent; naphthyridine; ortho-fused heteroarene
quinazolines Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.	4.23	4	0	azaarene; mancude organic heterobicyclic parent; ortho-fused heteroarene; quinazolines
thiazoles [no description available]	2.15	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
alpha-aminopyridine alpha-aminopyridine: RN given refers to parent cpd; structure in Merck Index, 9th ed, #485. aminopyridine : Compounds containing a pyridine skeleton substituted by one or more amine groups.	2.13	1	0
vidarabine adenine arabinoside : A purine nucleoside in which adenine is attached to arabinofuranose via a beta-N(9)-glycosidic bond.	5.94	3	2	beta-D-arabinoside; purine nucleoside	antineoplastic agent; bacterial metabolite; nucleoside antibiotic
betamethasone-17,21-dipropionate [no description available]	2.17	1	0	11beta-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; propanoate ester; steroid ester	antipsoriatic
cromolyn sodium Cromolyn Sodium: A chromone complex that acts by inhibiting the release of chemical mediators from sensitized MAST CELLS. It is used in the prophylactic treatment of both allergic and exercise-induced asthma, but does not affect an established asthmatic attack.. disodium cromoglycate : An organic sodium salt that is the disodium salt of cromoglycic acid.	2.17	1	0	organic sodium salt	anti-asthmatic drug; drug allergen
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	2.41	1	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
pirfenidone pirfenidone : A pyridone that is 2-pyridone substituted at positions 1 and 5 by phenyl and methyl groups respectively. An anti-inflammatory drug used for the treatment of idiopathic pulmonary fibrosis.	2.21	1	0	pyridone	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug
irinotecan [no description available]	2.31	1	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
chloranilic acid chloranilic acid: structure	2.41	1	0
bendamustine hydrochloride [no description available]	2.11	1	0
clofarabine [no description available]	3.41	1	0	adenosines; organofluorine compound	antimetabolite; antineoplastic agent
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	2.15	1	0	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
gefitinib [no description available]	3.41	1	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
methotrexate [no description available]	2.31	1	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
10-propargyl-10-deazaaminopterin 10-propargyl-10-deazaaminopterin: structure in first source. pralatrexate : A pteridine that is the N-4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl derivative of L-glutamic acid. Used for treatment of Peripheral T-Cell Lymphoma, an aggressive form of non-Hodgkins lymphoma.	3.41	1	0	N-acyl-L-glutamic acid; pteridines; terminal acetylenic compound	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
erlotinib [no description available]	3.41	1	0	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
lapatinib [no description available]	3.41	1	0	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
lenalidomide [no description available]	3.21	1	0	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator
s 1033 [no description available]	2.15	1	0	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
fludarabine [no description available]	5.94	3	2	purine nucleoside
thioguanine anhydrous Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.	3.41	1	0	2-aminopurines	anticoronaviral agent; antimetabolite; antineoplastic agent
nelarabine nelarabine: prodrug of ara-G. nelarabine : A purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G).	3.41	1	0	beta-D-arabinoside; monosaccharide derivative; purine nucleoside	antineoplastic agent; DNA synthesis inhibitor; prodrug
zd 6474 CH 331: structure in first source	3.41	1	0	aromatic ether; organobromine compound; organofluorine compound; piperidines; quinazolines; secondary amine	antineoplastic agent; tyrosine kinase inhibitor
ovalbumin Ovalbumin: An albumin obtained from the white of eggs. It is a member of the serpin superfamily.	2.08	1	0
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide: a TGF-beta type I receptor kinase activity inhibitor	3.31	1	0	benzamides; benzodioxoles; imidazoles; pyridines	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
alvocidib alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.	3.21	1	0	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
as 605240 5-quinoxalin-6-ylmethylenethiazolidine-2,4-dione: a PI3Kgamma inhibitor; structure in first source. (5Z)-5-(quinoxalin-6-ylmethylidene)-1,3-thiazolidine-2,4-dione : A quinoxaline derivative that is quinoxaline in which the hydrogen at position 6 is replaced by a (2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl group. It is a potent inhibitor of the PI3Kgamma, with an IC50 of 8 nM and inhibits the progression of joint inflammation and damage in both lymphocyte-independent and dependent mouse models of rheumatoid arthritis.	3.69	2	0	quinoxaline derivative; thiazolidinediones	anti-inflammatory agent; antirheumatic drug; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
palbociclib [no description available]	3.78	2	0	aminopyridine; aromatic ketone; cyclopentanes; piperidines; pyridopyrimidine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
everolimus [no description available]	2.17	1	0	cyclic acetal; cyclic ketone; ether; macrolide lactam; primary alcohol; secondary alcohol	anticoronaviral agent; antineoplastic agent; geroprotector; immunosuppressive agent; mTOR inhibitor
ly-2157299 LY-2157299: an orally active transforming growth factor beta receptor (TGF-beraR) kinase inhibitor. LY-2157299 : A pyrrolopyrazole that is 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole which is substituted at positions 2 and 3 by 6-methylpyridin-2-yl and 6-(aminocarbonyl)quinolin-4-yl groups, respectively. A Transforming growth factor-betaRI (TGF-betaRI) kinase inhibitor, it blocks TGF-beta-mediated tumor growth in glioblastoma.	3.31	1	0	aromatic amide; methylpyridines; monocarboxylic acid amide; pyrrolopyrazole; quinolines	antineoplastic agent; TGFbeta receptor antagonist
bibw 2992 [no description available]	3.41	1	0	aromatic ether; enamide; furans; monochlorobenzenes; organofluorine compound; quinazolines; secondary carboxamide; tertiary amino compound	antineoplastic agent; tyrosine kinase inhibitor
sd-208 [no description available]	3.31	1	0
tg100-115 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol: for treatment of ischemia reperfusion injury; structure in first source	3.31	1	0	pteridines
abt-737 [no description available]	2.11	1	0	aromatic amine; aryl sulfide; biphenyls; C-nitro compound; monochlorobenzenes; N-arylpiperazine; N-sulfonylcarboxamide; secondary amino compound; tertiary amino compound	anti-allergic agent; anti-inflammatory agent; antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
pf 00299804 dacomitinib: a pan-ERBB inhibitor. dacomitinib : A member of the class of quinazolines that is 7-methoxyquinazoline-4,6-diamine in which the amino group at position 4 is substituted by a 3-chloro-4-fluorophenyl group and the amino group at position 6 is substituted by an (E)-4-(piperidin-1-yl)but-2-enoyl group.	3.41	1	0	enamide; monochlorobenzenes; monofluorobenzenes; piperidines; quinazolines; secondary amino compound; secondary carboxamide; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
carfilzomib [no description available]	2.11	1	0	epoxide; morpholines; tetrapeptide	antineoplastic agent; proteasome inhibitor
idelalisib idelalisib: an antineoplastic agent and p110delta inhibitor; structure in first source. idelalisib : A member of the class of quinazolines that is 5-fluoro-3-phenylquinazolin-4-one in which the hydrogen at position 2 is replaced by a (1S)-1-(3H-purin-6-ylamino)propyl group. used for for the treatment of refractory indolent non-Hodgkin's lymphoma and relapsed chronic lymphocytic leukemia.	7.14	18	0	aromatic amine; organofluorine compound; purines; quinazolines; secondary amino compound	antineoplastic agent; apoptosis inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
cgp 57380 CGP 57380: inhibits the mitogen-activated protein kinase-interacting kinase Mnk1	3.31	1	0	pyrazolopyrimidine
zstk474 ZSTK-474 : A triamino-1,3,5-triazine that is 1,3,5-triazine in which two of the hydrogens have been replaced by morpholin-4-yl groups while the third hydrogen has been replaced by a 2-(difluoromethyl)benzimidazol-1-yl group. It is an inhibitor of phosphatidylinositol 3-kinase.	2.57	2	0	benzimidazoles; morpholines; organofluorine compound; triamino-1,3,5-triazine	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
in 1130 3-((5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl)methyl)benzamide: an activin receptor-like kinase-5 inhibitor; structure in first source	3.31	1	0
buparlisib NVP-BKM120: a pan class I PI3 kinase inhibitor with antineoplastic activity; structure in first source	2.13	1	0	aminopyridine; aminopyrimidine; morpholines; organofluorine compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
bms 777607 N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide: a Met kinase inhibitor; structure in first source	3.31	1	0	aromatic amide
sgi 1776 SGI 1776: a Pim kinase inhibitor; structure in first source	3.31	1	0	imidazoles
pci 32765 ibrutinib: a Btk protein inhibitor. ibrutinib : A member of the class of acrylamides that is (3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidine in which the piperidine nitrogen is replaced by an acryloyl group. A selective and covalent inhibitor of the enzyme Bruton's tyrosine kinase, it is used for treatment of B-cell malignancies.	7.93	12	2	acrylamides; aromatic amine; aromatic ether; N-acylpiperidine; pyrazolopyrimidine; tertiary carboxamide	antineoplastic agent; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
mk 2206 MK 2206: a protein kinase inhibitor and antineoplastic agent	2.17	1	0	organic heterotricyclic compound	EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor
navitoclax [no description available]	3.21	1	0	aryl sulfide; monochlorobenzenes; morpholines; N-sulfonylcarboxamide; organofluorine compound; piperazines; secondary amino compound; sulfone; tertiary amino compound	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
gsk 2126458 omipalisib: inhibitor of mTOR protein. omipalisib : A member of the class of quinolines that is quinoline which is substituted by pyridazin-4-yl and 5-[(2,4-difluorobenzene-1-sulfonyl)amino]-6-methoxypyridin-3-yl groups at positions 4 and 6, respectively. It is a highly potent inhibitor of PI3K and mTOR developed by GlaxoSmithKline and was previously in human phase 1 clinical trials for the treatment of idiopathic pulmonary fibrosis and solid tumors.	2.21	1	0	aromatic ether; difluorobenzene; pyridazines; pyridines; quinolines; sulfonamide	anticoronaviral agent; antineoplastic agent; autophagy inducer; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor; radiosensitizing agent
piperidines Piperidines: A family of hexahydropyridines.	7.18	8	2
ribociclib ribociclib: inhibits both CDK4 and CDK6	3.41	1	0
mk-8033 1-(3-(1-methyl-1H-pyrazol-4-yl)-5-oxo-5H-benzo(4,5)cyclohepta(1,2-b)pyridin-7-yl)-N-(pyridin-2-ylmethyl)methanesulfonamide: inhibits both Ron and c-Met kinases; structure in first source	3.31	1	0
dinaciclib [no description available]	3.21	1	0	pyrazolopyrimidine
gsk2292767 GSK2292767: inhibits phosphoinositide 3-kinase delta; structure in first source	2.13	1	0
abt-199 venetoclax: A BCL-2 inhibitor with antineoplastic activity that is used in the treatment of CHRONIC LYMPHOCYTIC LEUKEMIA associated with chromosome 17p deletion; structure in first source.. venetoclax : A member of the class of pyrrolopyridines that is a potent inhibitor of the antiapoptotic protein B-cell lymphoma 2. It is used for treamtment of chronic lymphocytic leukemia with 17p deletion.	8.34	6	2	aromatic ether; C-nitro compound; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; N-sulfonylcarboxamide; oxanes; pyrrolopyridine	antineoplastic agent; apoptosis inducer; B-cell lymphoma 2 inhibitor
ew-7197 vactosertib: a TGF-beta type I receptor kinase inhibitor with antifibrotic and antineoplastic activities; structure in first source	3.31	1	0
byl719 [no description available]	2.58	2	0	proline derivative
azd1208 [no description available]	3.31	1	0
epz-6438 tazemetostat: a histone methyltransferase EZH2 inhibitor with antineoplastic activity	3.51	1	0
nitrophenols Nitrophenols: PHENOLS carrying nitro group substituents.	2.11	1	0
pemetrexed pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).	3.41	1	0	N-acyl-L-glutamic acid; pyrrolopyrimidine	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; EC 2.1.1.45 (thymidylate synthase) inhibitor; EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
bay 80-6946 copanlisib: an antineoplastic agent with PI3K inhibitory activity; structure in first source. copanlisib : An imidazoquinazoline that is 2,3-dihydroimidazo[1,2-c]quinazoline substituted by (2-aminopyrimidine-5-carbonyl)amino, methoxy, and 3-(morpholin-4-yl)propoxy groups at positions 5, 7 and 8, respectively. It is a intravenous pan-class I PI3K inhibitor used for the treatment of relapsed follicular lymphoma in patients who have received at least 2 prior systemic therapies.	4.23	4	0

Condition	Indicated	Relationship Strength	Studies	Trials
Polyarthritis [description not available]	0	2.49	2	0
Asthma, Bronchial [description not available]	0	2.8	3	0
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	3.4	6	0
Libman-Sacks Disease [description not available]	0	2.49	2	0
Arthritis Acute or chronic inflammation of JOINTS.	0	2.49	2	0
Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL).	1	4.8	3	0
Lupus Erythematosus, Systemic A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow.	0	2.49	2	0
Respiratory Tract Diseases Diseases involving the RESPIRATORY SYSTEM.	0	2.13	1	0
Eczema, Atopic [description not available]	0	2.17	1	0
Dermatitis, Atopic A chronic inflammatory genetically determined disease of the skin marked by increased ability to form reagin (IgE), with increased susceptibility to allergic rhinitis and asthma, and hereditary disposition to a lowered threshold for pruritus. It is manifested by lichenification, excoriation, and crusting, mainly on the flexural surfaces of the elbow and knee. In infants it is known as infantile eczema.	0	2.17	1	0
Innate Inflammatory Response [description not available]	0	5.72	3	1
Benign Neoplasms [description not available]	0	4.72	5	0
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	5.72	3	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	1	7.88	10	0
Autoimmune Disease [description not available]	0	3.12	1	0
Autoimmune Diseases Disorders that are characterized by the production of antibodies that react with host tissues or immune effector cells that are autoreactive to endogenous peptides.	0	3.12	1	0
Adjuvant Arthritis [description not available]	0	2.21	1	0
Cryptogenic Fibrosing Alveolitis [description not available]	0	2.72	2	0
Idiopathic Pulmonary Fibrosis A common interstitial lung disease of unknown etiology, usually occurring between 50-70 years of age. Clinically, it is characterized by an insidious onset of breathlessness with exertion and a nonproductive cough, leading to progressive DYSPNEA. Pathological features show scant interstitial inflammation, patchy collagen fibrosis, prominent fibroblast proliferation foci, and microscopic honeycomb change.	0	2.72	2	0
Congenital Zika Syndrome [description not available]	0	2.25	1	0
Zika Virus Infection A viral disease transmitted by the bite of AEDES mosquitoes infected with ZIKA VIRUS. Its mild DENGUE-like symptoms include fever, rash, headaches and ARTHRALGIA. The viral infection during pregnancy, in rare cases, is associated with congenital brain and ocular abnormalities, called Congenital Zika Syndrome, including MICROCEPHALY and may also lead to GUILLAIN-BARRE SYNDROME.	0	2.25	1	0
Recrudescence [description not available]	0	2.72	2	0
Brill-Symmers Disease [description not available]	0	6.44	5	1
B-Cell Chronic Lymphocytic Leukemia [description not available]	0	12.15	32	8
Lymphoma, Follicular Malignant lymphoma in which the lymphomatous cells are clustered into identifiable nodules within the LYMPH NODES. The nodules resemble to some extent the GERMINAL CENTER of lymph node follicles and most likely represent neoplastic proliferation of lymph node-derived follicular center B-LYMPHOCYTES.	1	10.2	10	2
Leukemia, Lymphocytic, Chronic, B-Cell A chronic leukemia characterized by abnormal B-lymphocytes and often generalized lymphadenopathy. In patients presenting predominately with blood and bone marrow involvement it is called chronic lymphocytic leukemia (CLL); in those predominately with enlarged lymph nodes it is called small lymphocytic lymphoma. These terms represent spectrums of the same disease.	1	14.15	32	8
Allodynia [description not available]	0	2.41	1	0
Nerve Pain [description not available]	0	2.41	1	0
Ache [description not available]	0	2.41	1	0
Peripheral Nerve Diseases [description not available]	0	2.41	1	0
Neuralgia Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.	0	2.41	1	0
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	0	2.41	1	0
Peripheral Nervous System Diseases Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.	0	2.41	1	0
Local Neoplasm Recurrence [description not available]	0	7.01	4	2
Cardiac Toxicity [description not available]	0	2.6	1	0
Cardiotoxicity Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.	0	2.6	1	0
Diffuse Lymphocytic Lymphoma, Poorly-Differentiated [description not available]	0	5.5	4	1
Diffuse Mixed Small and Large Cell Lymphoma [description not available]	0	7.46	5	3
B-Cell Lymphoma [description not available]	0	3.84	3	0
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	0	6.65	3	1
Lymphoma, Non-Hodgkin Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.	1	9.46	5	3
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	0	6.5	4	2
Lymphoma, B-Cell A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.	0	3.84	3	0
Lymphoma, Mantle-Cell A form of non-Hodgkin lymphoma having a usually diffuse pattern with both small and medium lymphocytes and small cleaved cells. It accounts for about 5% of adult non-Hodgkin lymphomas in the United States and Europe. The majority of mantle-cell lymphomas are associated with a t(11;14) translocation resulting in overexpression of the CYCLIN D1 gene (GENES, BCL-1).	0	5.5	4	1
T-Cell Lymphoma [description not available]	0	2.21	1	0
Lymphoma, T-Cell A group of heterogeneous lymphoid tumors representing malignant transformations of T-lymphocytes.	0	2.21	1	0
Disease Exacerbation [description not available]	0	4.07	2	1
Thrombopenia [description not available]	0	3.64	1	1
Diffuse Large B-Cell Lymphoma [description not available]	0	3.64	1	1
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	0	3.64	1	1
Lymphoma, Large B-Cell, Diffuse Malignant lymphoma composed of large B lymphoid cells whose nuclear size can exceed normal macrophage nuclei, or more than twice the size of a normal lymphocyte. The pattern is predominantly diffuse. Most of these lymphomas represent the malignant counterpart of B-lymphocytes at midstage in the process of differentiation.	1	5.64	1	1
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	0	2.31	1	0
Hematologic Malignancies [description not available]	0	5.58	5	1
Duncan Disease [description not available]	0	2.25	1	0
Lymphoproliferative Disorders Disorders characterized by proliferation of lymphoid tissue, general or unspecified.	0	2.25	1	0
Hematologic Neoplasms Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.	1	7.58	5	1
Infection [description not available]	0	3.17	1	0
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	0	3.17	1	0
Colitis Inflammation of the COLON section of the large intestine (INTESTINE, LARGE), usually with symptoms such as DIARRHEA (often with blood and mucus), ABDOMINAL PAIN, and FEVER.	0	3.17	1	0
Infections Invasion of the host organism by microorganisms or their toxins or by parasites that can cause pathological conditions or diseases.	0	3.17	1	0
Pneumonia Infection of the lung often accompanied by inflammation.	0	3.17	1	0
Lymphoma, T Cell, Peripheral [description not available]	0	4.94	2	1
Lymphoma, T-Cell, Peripheral A group of malignant lymphomas thought to derive from peripheral T-lymphocytes in lymph nodes and other nonlymphoid sites. They include a broad spectrum of lymphocyte morphology, but in all instances express T-cell markers admixed with epithelioid histiocytes, plasma cells, and eosinophils. Although markedly similar to large-cell immunoblastic lymphoma (LYMPHOMA, LARGE-CELL, IMMUNOBLASTIC), this group's unique features warrant separate treatment.	1	6.94	2	1
Granulocytic Leukemia, Chronic [description not available]	0	2.15	1	0
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.	0	2.15	1	0
Acute Lymphoid Leukemia [description not available]	0	2.17	1	0
Precursor Cell Lymphoblastic Leukemia-Lymphoma A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.	1	4.17	1	0
Cancer of Skin [description not available]	0	4.48	1	1
Cutaneous T-Cell Lymphoma [description not available]	0	4.48	1	1
Skin Neoplasms Tumors or cancer of the SKIN.	0	4.48	1	1
Lymphoma, T-Cell, Cutaneous A group of lymphomas exhibiting clonal expansion of malignant T-lymphocytes arrested at varying stages of differentiation as well as malignant infiltration of the skin. MYCOSIS FUNGOIDES; SEZARY SYNDROME; LYMPHOMATOID PAPULOSIS; and PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA are the best characterized of these disorders.	0	4.48	1	1
Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.	0	2.17	1	0
Leukemia, Pre-B-Cell [description not available]	0	2.17	1	0
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma A leukemia/lymphoma found predominately in children and adolescents and characterized by a high number of lymphoblasts and solid tumor lesions. Frequent sites involve LYMPH NODES, skin, and bones. It most commonly presents as leukemia.	0	2.17	1	0
EBV Infections [description not available]	0	2.17	1	0
Epstein-Barr Virus Infections Infection with human herpesvirus 4 (HERPESVIRUS 4, HUMAN); which may facilitate the development of various lymphoproliferative disorders. These include BURKITT LYMPHOMA (African type), INFECTIOUS MONONUCLEOSIS, and oral hairy leukoplakia (LEUKOPLAKIA, HAIRY).	0	2.17	1	0
Exanthem [description not available]	0	3.56	1	1
Exanthema Diseases in which skin eruptions or rashes are a prominent manifestation. Classically, six such diseases were described with similar rashes; they were numbered in the order in which they were reported. Only the fourth (Duke's disease), fifth (ERYTHEMA INFECTIOSUM), and sixth (EXANTHEMA SUBITUM) numeric designations survive as occasional synonyms in current terminology.	0	3.56	1	1
Adverse Drug Event [description not available]	0	4.56	2	2
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	0	4.56	2	2
Rheumatoid Arthritis [description not available]	0	2.1	1	0
Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated.	1	4.1	1	0
Cells, Neoplasm Circulating [description not available]	0	2.11	1	0
Acute Myelogenous Leukemia [description not available]	0	2.13	1	0
Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.	0	2.13	1	0
Hypophysitis Inflammation of the PITUITARY GLAND.	0	2.15	1	0
Genome Instability [description not available]	0	2.15	1	0
Chromosomal Translocation [description not available]	0	2.15	1	0

ipi-145

Cross-References

Synonyms (66)

Research Excerpts

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (12)

Potency Measurements

Inhibition Measurements

Biological Processes (184)

Molecular Functions (46)

Ceullar Components (34)

Bioassays (73)

Research

Studies (78)

Market Indicators

Research Demand Index: 20.68

Study Types

ipi-145

Cross-References

Synonyms (66)

Research Excerpts

Toxicity

Pharmacokinetics

Bioavailability

Dosage Studied

Drug Classes (1)

Protein Targets (12)

Potency Measurements

Inhibition Measurements

Biological Processes (184)

Molecular Functions (46)

Ceullar Components (34)

Bioassays (73)

Research

Studies (78)

Market Indicators

Research Demand Index: 20.68

Study Types

Related Drugs (67)

Related Conditions (88)